YUTA IBUKI

Last Updated :2025/04/02

Affiliations, Positions
Hiroshima University Hospital(Medical), Assistant Professor
E-mail
yibukihiroshima-u.ac.jp

Basic Information

Academic Degrees

  • Hiroshima University

Research Activities

Academic Papers

  1. Association between prognosis and lymph node status using 18F-fluorodeoxyglucose-positron emission tomography in esophageal squamous cell carcinoma treated with esophagectomy post-neoadjuvant chemotherapy, World J Surg ., 48(3), 650-661, 202403
  2. Prognostic factors for esophageal squamous cell carcinoma without pathological lymph node metastasis after neoadjuvant therapy and surgery, World J Surg ., 48(2), 416-426, 202402
  3. The treatment efficacy and prognosis of each treatment in early postoperative recurrence of esophageal squamous cell carcinoma, Surg Today ., 54(1), 53-63, 202401
  4. Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma, Onco Targets Ther ., 20230410
  5. Relationship of Immune-Related Adverse Events with Tumor Response and Prognosis in Esophageal Squamous Cell Carcinoma Following Nivolumab Monotherapy, CANCERS, 16(20), 202410
    Link to Paper Search Results by DOI
  6. Risk factors for recurrence of esophageal squamous cell carcinoma after pathological complete response to neoadjuvant therapy followed by esophagectomy, WORLD JOURNAL OF SURGERY, 48(7), 1700-1709, 202407
    Link to Paper Search Results by DOI
  7. Association between prognosis and lymph node status using 18F-fluorodeoxyglucose-positron emission tomography in esophageal squamous cell carcinoma treated with esophagectomy post-neoadjuvant chemotherapy, WORLD JOURNAL OF SURGERY, 48(3), 650-661, 202403
    Link to Paper Search Results by DOI
  8. Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma, Front Oncol ., 20230417